Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Gregory

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2019
Targeting Glutamine Metabolism and Redox State for Leukemia TherapyMark A Gregory, Travis Nemkov, Hae J Park, et al.
American Journal of Hematology|June 4, 2014
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemiaLori A Gardner, Jelena Klawitter, Mark A Gregory, et al.
Cancer Cell|July 9, 2010
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-AblMark A Gregory, Tzu L Phang, Paolo Neviani, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemiaMark A Gregory, Angelo D'Alessandro, Francesca Alvarez-Calderon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2014
Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbationsFrancesca Alvarez-Calderon, Mark A Gregory, Catherine Pham-Danis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerAnna Spreafico, John J Tentler, Todd M Pitts, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2019
Targeting Glutamine Metabolism and Redox State for Leukemia TherapyMark A Gregory, Travis Nemkov, Hae J Park, et al.
American Journal of Hematology|June 4, 2014
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemiaLori A Gardner, Jelena Klawitter, Mark A Gregory, et al.
Cancer Cell|July 9, 2010
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-AblMark A Gregory, Tzu L Phang, Paolo Neviani, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemiaMark A Gregory, Angelo D'Alessandro, Francesca Alvarez-Calderon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2014
Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbationsFrancesca Alvarez-Calderon, Mark A Gregory, Catherine Pham-Danis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerAnna Spreafico, John J Tentler, Todd M Pitts, et al.
Pageof 2